1110007L15Rik activators comprise a diverse array of chemical compounds that indirectly elevate the functional activity of 1110007L15Rik through a variety of signaling mechanisms. Forskolin and IBMX, through their activities on adenylyl cyclase and phosphodiesterases respectively, increase intracellular cAMP levels which in turn activate PKA; this activation can lead to the phosphorylation of various proteins that are part of the pathways where 1110007L15Rik is a component, thereby enhancing its activity. Similarly, PMA activates PKC, which influences multiple signaling cascades that can intersect with 1110007L15Rik's regulatory networks, potentially leading to its enhanced activity. The calcium ionophores, Ionomycin and A23187, raise intracellular calcium levels, which could activate calcium-sensitive proteins and enzymes that may indirectly augment 1110007L15Rik activity by modulating relevant signaling pathways.
RIKEN cDNA 1110007L15 gene Activators are a diverse array of chemical compounds that enhance the functional activity of the RIKEN cDNA 1110007L15 gene through various intracellular signaling pathways. For example, Forskolin raises the levels of cAMP within the cell, which in turn activates PKA. Since PKA phosphorylates a multitude of substrates, it is plausible that the RIKEN cDNA 1110007L15 gene could be one of them, resulting in its functional enhancement. Moreover, PMA directly activates PKC, which is known for its role in phosphorylating proteins and changing theiractivity-potentially including the RIKEN cDNA 1110007L15 gene. Ionomycin and A23187, by increasing intracellular calcium levels, can activate calcium-dependent kinases which may target the RIKEN cDNA 1110007L15 gene, thus enhancing its activity. Similarly, EGCG, despite its role as a kinase inhibitor, may indirectly activate pathways that lead to the phosphorylation and activation of the RIKEN cDNA 1110007L15 gene. Sphingosine-1-phosphate engages GPCR-mediated pathways, which are intricate networks capable of influencing a wide range of proteins, including the RIKEN cDNA 1110007L15 gene.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels, which may indirectly enhance the activity of 1110007L15Rik through PKA signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC) which can lead to the activation of signaling pathways that may indirectly enhance the activity of 1110007L15Rik. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially stimulating calcium-dependent kinases and phosphatases that could enhance 1110007L15Rik activity. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP is a cAMP analog resistant to degradation and can activate PKA, which may then phosphorylate substrates that enhance 1110007L15Rik activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore, raising intracellular calcium and potentially enhancing the activity of 1110007L15Rik through calcium-dependent signaling mechanisms. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit certain types of kinases, which could remove inhibitory phosphorylations from proteins in pathways that include 1110007L15Rik, thus enhancing its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P activates sphingosine-1-phosphate receptors, which may enhance 1110007L15Rik activity by modulating intracellular signaling pathways that intersect with 1110007L15Rik's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which could enhance 1110007L15Rik activity by altering signaling pathways downstream of PI3K that affect 1110007L15Rik's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which may shift signaling dynamics to enhance 1110007L15Rik activity by influencing pathways that interact with p38 MAPK. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can enhance the activity of 1110007L15Rik by potentially reducing competitive phosphorylation events that might otherwise suppress 1110007L15Rik's function. | ||||||